Atossa Therapeutics Receives Approval from Swedish Regulators to Initiate Phase 2 Clinical Study of Oral Endoxifen to Reduce Mammographic Breast DensityGlobeNewsWire • 06/11/21
Atossa Therapeutics Reveals Final Endoxifen Data From Mid-Stage Breast Cancer TrialBenzinga • 06/09/21
Atossa Therapeutics Announces Final Data from Phase 2 Endoxifen Breast Cancer Study Primary Endpoint Met: 65.1% Reduction in Biomarker Ki-67; Secondary Endpoint Met: Endoxifen Safe and Well ToleratedGlobeNewsWire • 06/09/21
Atossa Therapeutics to Release Final Data from Phase 2 Study of Endoxifen Administered to Breast Cancer Patients Prior to Surgery at a Webinar at 8 am Pacific Time on June 9, 2021GlobeNewsWire • 06/07/21
New Research Demonstrates Claims that the Wuhan Institute of Virology had no cases of COVID-19 are not crediblePRNewsWire • 05/27/21
Physician-Scientist Dr. Steven Quay to Brief the U.S. Congress On His Research Investigating the Origin of the COVID-19 PandemicPRNewsWire • 05/21/21
Atossa Therapeutics Announces First Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/14/21
Atossa Therapeutics to Participate at the Investor Summit Conference and Present to Investors on May 18, 2021GlobeNewsWire • 05/14/21
Atossa Therapeutics Urges Shareholders to Vote on Proposals Ahead of its Annual Stockholder Meeting May 14, 2021 at 1:00 PM Pacific TimeGlobeNewsWire • 05/11/21
